Reflux Esophagitis Pipeline by Companies, Assessment by Target Review Report 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —The following research report is a compilation of high-end data that has been researched thoroughly to highlight the various trends prevailing across the Reflux Esophagitis market. This study is titled “Reflux Esophagitis-Pipeline Review, H2 2019”, which carefully examines several vital factors such as market share, market revenue, market dynamics and competitive scenario active in the target market for the period 2019

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519481

Reflux Esophagitis – Pipeline Review, H2 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis – Pipeline Review, H2 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 7, 7, 4, 1 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Browse Complete Report at https://www.marketresearchhub.com/report/reflux-esophagitis-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Overview
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Handa Pharmaceuticals LLC
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Sam-A Pharm Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
XuanZhu Pharma Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Drug Profiles
(esomeprazole + sodium bicarbonate) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azeloprazole sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceclazepide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-30065 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colesevelam – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-009 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IYHCR-17 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole DR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SA-15001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan – Drug Profile

Make An Enquiry About This Report https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519481

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick